<DOC>
	<DOC>NCT01166659</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and effectiveness of CyPass implantation as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) who have failed at least one class of topical medical therapy</brief_summary>
	<brief_title>Study of CyPass Implantation In Patients With Open Angle Glaucoma Refractory to Single or Multi-agent Topical Therapy</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<criteria>Diagnosis of POAG Medicated IOP ≥ 21 and ≤ 35 mmHg Use of 1 4 topical IOP lowering medications Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma Use of oral hypotensive medication treatment for glaucoma Previous incisional glaucoma surgery, or any combined cataractglaucoma procedure Clinically significant ocular pathology other than POAG</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Glaucoma device</keyword>
	<keyword>Glaucoma surgery</keyword>
	<keyword>Intraocular pressure</keyword>
</DOC>